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The cytokine interleukin 1B (IL-l/?) induces the expression of an isoform of nitric oxide synthase (NOS) in insulin-producing cells which is similar 
to that expressed in activated macrophages. In the present study we show that IL-l/J-induced expression of NOS mRNA in these cells is preceded 
by expression of c-j& mRNA. Moreover, the stimulatory effects of recombinant IL-l/I on NOS mRNA expression are prevented by co-incubation 
with an inhibitor of gene transcription (actinomycin D) or an inhibitor of protein synthesis (cycloheximide). These data suggest that IL-lb-induced 
NOS mRNA expression may be mediated by transcription of immediate early response genes, and that c&s may be one of these genes. 
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1. INTRODUCTION 
Long-term in vitro exposure of rodent pancreatic is- 
lets to the cytokine IL-l (IL-l) induces suppression of 
insulin release and (pro)insulin biosynthesis, and may 
lead to p-cell death [1,2]. We and other groups have 
recently characterized some of the mechanisms behind 
the effects of IL-l on rat islets. Thus, the actions of the 
cytokine requires binding to membrane receptors [3,4], 
induction of gene transcription and protein translation 
[5,6]. After an initial stimulation of islet oxidative me- 
tabolism and insulin release, there is a progressive func- 
tional inhibition [ 1,2]. This is caused by formation of the 
reactive compound, nitric oxide (NO) [7,8], which in- 
duces an impairment in mitochondrial function and de- 
creases ATP production 121, probably by impairing the 
function of the Krebs cycle enzyme, aconitase [8]. 
course of the effects of recombinant IL-l/I on NOS and 
c-fos mRNA expression in the clonal insulin secretory 
cell line, HIT-T15 cells (HIT cells) [13]. Moreover, the 
effects of blockers of gene transcription (actinomycin 
D) or blockers of protein synthesis (cycloheximide) on 
NOS mRNA expression were also evaluated. Finally, 
we characterized the expression of the mRNAs for the 
types I and II IL-l receptors in these cells. 
2. EXPERIMENTAL 
2.1. Materials 
NO formation is controlled by the enzyme, nitric 
oxide synthase (NOS). Different tissues present differ- 
ent isoforms of NOS [9], and we have recently shown 
that IL- l/I induces the expression of an isoform of NOS 
in insulin-producing cells, which is similar to that ob- 
served in activated macrophages [lo]. Considering that 
NO generation may be a final common pathway for 
cytokine(s)- and/or macrophage-induced B-cell damage 
in insulin-dependent diabetes mellitus (IDDM) [ 11,121, 
it is of relevance to further characterize the genetic con- 
trol of the inducible form of NOS in insulin-producing 
cells [lo]. In the current study, we investigated the time- 
Human recombinant IL-lb (rIL-lp) was a kind gift from Dr. K. 
Bendtzen, Laboratory of Medical Immunology, Righospitalet, 
Copenhagen, Denmark. rIL-1B was produced by Immunex Research 
and Development Corp. (Seattle, WA, USA) and presented a biolog- 
ical activity of 50 U/ng [14]. The chemicals were obtained from the 
following sources: FastTrack mRNA isolation kit from Invitrogen 
Corp. (San Diego, CA, USA); Megaprime DNA labelling system and 
[a-“P]dCTP from Amersham International (Amersham, UK); Mag- 
naGraph nylon transfer membrane from Micron Separations Inc. 
(Westboro, MA, USA); actinomycin D from Sigma Chemicals (St. 
Louis, MO, USA); cycloheximide (Calbiochem-Bohering Corp, La 
Jolla, CA. USA). All other chemicals or analytical grade were ob- 
tamed from E. Merck (Darmstadt, Germany) or from Sigma Chem- 
icals 
2.2. Metho& 
Correspondence nddress: D.L. Eizirik, Department of Medical Cell 
Biology, Uppsala University, Uppsala S-751 23. Sweden. Fax: (46) 
(18) 556 401. 
The clonal hamster insulin secretory cell line, HIT-T 15 (HIT cells) 
[13] was originally obtained from Dr. S.J. Ashcroft, Oxford, UK. 
Growing HIT cells were trypsinized and subcultured in RPM1 1640 
supplemented with 10% (v/v) FCS, as previously described [lo]. 
Exposure of the HIT cells to rIL-l/3 (1 &ml) was performed for 
30 min or 1.2.4.6 and 8 h as described above. HIT cells were exposed 
to rIL-l/J (1 &ml) in the presence of actinomycin D (5 pg/ml) or 
cycloheximide (20@ml) for a 6-h period. The concentration of cyclo- 
heximtde used (20 ,&ml) decreases the total protein biosynthesis of 
HIT cell to less than 10% of control values (data not shown). Follow- 
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ing rIL-l/I exposure, aliquots of the culture medium (80 ~1; collected 
in triplicate) were deproteinized and the nitrite content determined as 
previously described [8]. 
For Northern blot analysis, poly(A)‘-selected mRNA was isolated 
from 10’ to 3 x 10’ cells using a FastTrack mRNA isolation kit. Fol- 
lowing isolation, the mRNA samples (24 pg) were electrophoresed 
on an agarose gel, transferred onto a nylon membrane [15], and se- 
quentially hybridized to 32P-labelled cDNA probes coding either for 
the inducible form of NOS [16] (a kind gift from Drs. CR. Lyons, G.J. 
Orloff and J.M. Cunningham, Hematology-Oncology Division, Har- 
vard Medical School, Boston, MA, USA) or for the viral protoonco- 
gene, c-fos [17] (a kind gift of Dr. Natalie Teich, Imperial Cancer 
Research Fund, London, UK). As an internal control, the membranes 
were re-hybridized to a cDNA probe coding for the human glyceralde- 
hyde- 3-phosphate dehydrogenase gene (GAPDH [18]) (obtained from 
American Type Culture Collection, Rockville, MD, USA). GAPDH 
mRNA levels are unaffected by large variations in /I-cell functional 
activity [19] or by different stages of cell growth, in distinct cell lines 
[20]. In a separate series of experiments, mRNA (5 pg) obtained from 
control HIT cells. or HIT cells exposed for 6 h to rIL-l/I, was hybrid- 
ized with cDNA probes encoding the murine forms for either type I 
or type II IL-l receptors [21,22] (a kind gift of Dr. John Sims, Depart- 
ment of Molecular Biology, Immunex Research and Development 
Corp.). Hybridization and autoradiography were performed as previ- 
ously described [15]. 
Data are presented as means f S.E.M., and groups of data were 
compared using paired or unpaired Student’s r-test as appropriate. 
3. RESULTS AND DISCUSSION 
The effects of IL-l on different cell types are exerted 
via specific receptors for IL-l [23]. The two better char- 
acterized IL-l receptors are the M, 80,000 type I recep- 
tor, present mostly in T-lymphocytes and fibroblasts, 
and the M, 60,000 type II receptor, present mostly in 
B-lymphocytes, bone marrow cells and hepatoma cells 
[21-231. In order to obtain information regarding the 
type(s) of IL-l receptor(s) present in insulin-producing 
cells, mRNA obtained from HIT cells was sequentially 
hybridized with cDNAs encoding the type I and the 
type II IL-l receptors. As shown in Fig. 1, HIT cells 
expressed a 5.0 kb mRNA for the type I IL-l receptor, 
and the mRNA content was not modified by 6 h (Fig. 
1) or 24 h (data not shown) exposure to rIL-lp (1 ng/ 
ml). When the blots were re-hybridized with a type II 
IL-l receptor probe (Fig. l), two major bands, esti- 
mated as 1.5 and 0.5 kb, were detected. The 1.5 kb band 
is similar to the type II IL-l receptor mRNA previously 
described in different B-lymphocyte cell lines [22]. In- 
deed, in another experimental series in which mRNA 
obtained either from HIT cells or from the murine B cell 
line, M 12.4.1.C 3 (a kind gift from Drs. E. Michaelson 
and R. Holmdahl, Department of Medical and Physio- 
logical Chemistry, Uppsala University, Uppsala, Swe- 
den), were hybridized in parallel with the type II IL-l 
receptor probe (data not shown), both HIT cells and 
murine B cells showed a similar 1.5 kb band, but only 
HIT cells presented the smaller 0.5 kb band. Interest- 
ingly, the larger band seemed to be induced by IL-1 in 
HIT cells, both after 6 h (Fig. 1) or 24 h (not shown) 
exposure to the cytokine. Thus, HIT cells present 
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Fig. 1. Northern blots hybridized with a probe for the type I IL-1 
receptor (top), with a probe for the type II IL-l receptor (middle) or 
a probe for GAPDH (bottom). HIT cells were cultured under control 
conditions (lane 1) or exposed to rIL-l/3 for 6 h (lane 2), and then 
harvested for mRNA extraction. The figure is representative of 2 
separate xperiments. 
mRNAs for both the type I and type II IL-l receptors. 
Similar observations were made in some B- and T-lym- 
phocyte cell lines [22]. Previous studies, with co-incuba- 
tion of insulin-producing cells with IL-l and/or an 
human interleukin- 1 receptor antagonist protein 
(IRAP), which binds preferentially to the murine type 
I IL-l receptor [24], have shown complete blocking of 
the suppressive ffects of IL-l by IRAP [4]. Moreover, 
antibody blocking of the murine type I IL-l receptor 
also protected these cells against IL-l [25]. Given these 
previous observations, the presence of type II IL-l re- 
ceptor mRNA in HIT cells is surprising. It still remains 
to be clarified if the signalling pathways used by types 
I and II IL-l receptors are similar. When available, this 
information may be of relevance to further explain the 
different actions of IL-l on insulin-producing cells [2]. 
Following binding to surface receptors, IL-l/I 
transduces a signal(s) in insulin-producing cells that 
leads to increased expression of the inducible form of 
NOS [lo], followed by NO formation [7,8]. In order to 
further investigate this issue, we performed time-course 
studies on the actions of rIL-l/? on NOS mRNA expres- 
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Fig. 2. Northern blot analysis of HIT cells at different time points of culture in the presence of the cytokine rIL-lp (1 @ml). Hybridizations were 
performed with cDNAs encoding for the inducible form of NOS (top), the c-f&r protooncogene (middle) or GADPH (bottom). Lane 1, control; 
lane 2, rIL-ID lh; lane 3, rIL-l/l2 h; lane 4. rIL-lD, 4 h; lane 5. rIL-I/% 6 h; lane 6, rIL-Ia, 8 h. The figure is representative of 3 separate experiments. 
sion (Fig. 2). After 4 h exposure to the cytokine, there 
was already a clear induction of a 5.0 kb mRNA, similar 
to previous observations in activated macrophages [16] 
and HIT cells [lo]. The amounts of this mRNA were 
further increased after 6 and 8 h (Fig. 2). Parallel deter- 
minations of nitrite, an end product of NO, in the cul- 
ture medium showed a similar pattern as observed with 
NOS mRNA, i.e. an initial increase in nitrite accumula- 
tion after 4 h rIL-l/I exposure, with further increases in 
nitrite content after 6 and 8 h (Fig. 3). 
IL- 1 induces an early increase c-jiis mRNA in pancre- 
atic B-cells [26]. The protein product of the c-fos gene 
has been proposed to function as a transcriptional regu- 
lator, which couples early signal transduction to late 
nuclear events [27]. Thus, it is conceivable that the ef- 
fects of IL-l in insulin-producing cells are mediated by 
early transcription of the c-fos gene, followed by synthe- 
sis of the Fos protein (and/or other early response 
genes), leading to induction of NOS transcription. In 
line with this possibility, re-hybridization of the blots 
(Fig. 2) with a probe for c-fos revealed an early and 
transitory (30 min-1 h; Fig. 2 and data not shown) 
increase in c-fos mRNA contents, preceding by 2-3 h 
the increase in NOS mRNA. It is noteworthy that after 
8 h, coinciding with the observed increase in NOS 
mRNA and nitrite production, there was a second in- 
crease in c-fos mRNA content. Besides its role as early 
64 
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Fig. 3. rIL-IjI-induced medium nitrite accumulation in HIT cells ex- 
posed for different amounts of time to the cytokine (1 ng/ml), as 
compared to nitrite accumulation into the medium of HIT cells cul- 
tured in the absence of rIL-I@. At each time point, the medium nitrite 
content observed in control HIT cells was subtracted from the values 
observed in the respective rIL-l/3-treated HIT cells. Results are 
means + S.E.M. for 34 separate experiments 
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Fig. 4. Northern blot analysis of HIT cells exposed for 6 h to rIL-l/I and/or actinomycin D (5 @ml) or cycloheximide (20 &ml). Hybridizations 
were performed with cDNAs encoding for the inducible form of NOS (top) or GADPH (bottom). Lane 1, control; lane 2, cycloheximide; lane 3, 
actinomycin D; lane 4, rIL-I/?; lane 5, rIL-l/3 + cycloheximide; lane 6, rIL-l/I + actinomycin D. The figure is representative of3 separate xperiments. 
response gene, c-fos can also be induced as a late re- 
sponse to cell damage and/or NO generation [27,28]. 
Indeed, in separate experiments, where HIT cells were 
exposed to the alkylating agents, streptozotocin or 
methyl methanesulfonate (Bjiirklund and Eizirik, un- 
published data), c-fos mRNA was induced after 3-4 h, 
and this increase in mRNA lasted for at least 7-9 h. 
Thus, it is conceivable that, in the current series of 
experiments, we observed two facets of c-fos mRNA 
induction: an initial and transitory induction of c-fos by 
IL- 1, probably playing a role of an early response gene, 
followed by a second induction of the gene, probably as 
a consequence of NO-induced cell damage. 
The role of transcriptional regulation and protein 
synthesis for rIL-l/?-induced NOS mRNA expression 
were evaluated in a second series of experiments, using 
the RNA synthesis inhibitor, actinomycin D, and the 
protein synthesis inhibitor, cycloheximide (Fig. 4). Both 
drugs has previously been shown to prevent IL-l-in- 
duced NO production [8,29] and to protect B-cells 
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Fig. 5. Inhibition of nitrite accumulation by actinomycin D (Act, 5 &ml) or cycloheximide (Ch, 20 &ml) in HIT cells exposed for 6 h to rIL-l/3 
(1 @ml). Results are means k S.E.M. for 6 separate xperiments. ‘P < 0.02 and “P < 0.01 when compared to HIT cells exposed to rIL-l/I alone. 
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against suppressive ffects of the cytokine [5,6]. Actino- 
mycin D completely prevented the rIL-l/3-induced in- 
crease in NOS mRNA (Fig. 4). and nitrite accumulation 
into the culture medium (Fig. 5). This observation sug- 
gests that expression of IL-l-induced NOS mRNA in 
HIT cells is regulated, at least in part, at the transcrip- 
tional level. Cycloheximide also prevented the increase 
in NOS mRNA and, at least partially, prevented rIL- 
l/?-induced nitrite accumulation into the medium (Figs. 
4 and 5). These effects of cycloheximide suggest hat 
synthesis of new proteins is a prerequisite for induction 
of NOS mRNA. As discussed above, it is conceivable 
that one of these proteins is the protein encoded by the 
c-j& protooncogene. 
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